#ESMOIO22 - Twitter Hashtag

over 3 years ago

1) Welcome to a new #accredited #tweetorial, "Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC," featuring the highlights of a symposium presented at the #ESMOIO22 congress. @myESMO #LCSM #FOAMed

onc_ce's tweet photo. 1) Welcome to a new #accredited #tweetorial, "Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC," featuring the highlights of a symposium presented at the #ESMOIO22 congress.
@myESMO #LCSM #FOAMed https://t.co/MH3uqZaytE

1

28

5

13

4K

Anniina Färkkilä @afarkkila

almost 4 years ago

Thank you @myESMO #ESMOIO22 for the invitation and interesring discussions!

0

22

0

Bertrand Delsuc @BertrandBio

almost 4 years ago

Innovent Presents Phase Ib Clinical Data of IBI939 (Anti-#TIGIT mAb) in Previously Untreated PD-L1-selected NSCLC at #ESMOIO22 interestingly that's randomized 2:1 IBI939+simti vs simti alone n=40 TPS≥50% (27 vs 13) cORR 64.3% vs 57.2% https://t.co/XUFfXhYShj

1

11

4

1

0

Jarushka Naidoo @DrJNaidoo

almost 4 years ago · Dublin City

Great thread on potential relevance of ctDNA on adjuvant therapy in early stage NSCLC, analysis of impower010 #ESMOIO22 @myESMO @EnriquetaFelip #LCSM

Stephen V Liu, MD

@StephenVLiu

almost 4 years ago

Nice update on ctDNA in IMp010 from #ESMOImmuno22 by Dr. @EnriquetaFelip. Atezolizumab is our FDA approved adjuvant option for resected stage II/III NSCLC with PDL1 ≥1% (≥50% for EMA). Here, we see more granularity on significance of detectable ctDNA post-surgery.

StephenVLiu's tweet photo. Nice update on ctDNA in IMp010 from #ESMOImmuno22 by Dr. @EnriquetaFelip. Atezolizumab is our FDA approved adjuvant option for resected stage II/III NSCLC with PDL1 ≥1% (≥50% for EMA). Here, we see more granularity on significance of detectable ctDNA post-surgery. https://t.co/sx7pkZgX5x

4

93

30

18

0

14

3

1

0

1stOncology @1stOncology

almost 4 years ago

#Immunocore presents #OvarianCancer expansion data for #ImmTAC candidate #IMCC103C targeting #MAGEA4 #ESMOIO22 $IMCR https://t.co/6exc3UwMqY

0

1

0

Owkin

@OwkinScience

almost 4 years ago

Today at #ESMOIO22, Lucie Gillet of Owkin and Dr. @VanherseckeL of @BERGONIE33 explained our research on #deeplearning to predict the tertiary lymphoid structures (#TLS) status of patients from digitized HE slides used in the #clinical workflow. @myESMO

OwkinScience's tweet photo. Today at #ESMOIO22, Lucie Gillet of Owkin and Dr. @VanherseckeL of @BERGONIE33 explained our research on #deeplearning to predict the tertiary lymphoid structures (#TLS) status of patients from digitized HE slides used in the #clinical workflow.

@myESMO https://t.co/hWHSsUp6Xn

0

8

2

1

0

Owkin

@OwkinScience

almost 4 years ago

At 12:30pm CET on December 8th at #ESMOIO22, hear Lucie Gillet of Owkin and Dr. Lucile Vanhersecke of @BERGONIE33, present our research on the prognostic power of #deeplearning to predict the #TLS status of patients from #digitalpathology HE slides. @myESMO

OwkinScience's tweet photo. At 12:30pm CET on December 8th at #ESMOIO22, hear Lucie Gillet of Owkin and Dr. Lucile Vanhersecke of @BERGONIE33, present our research on the prognostic power of #deeplearning to predict the #TLS status of patients from #digitalpathology HE slides.

@myESMO https://t.co/k6XQNNk49J

0

5

1

0

Innate Pharma @InnatePharma

almost 4 years ago

Three posters showcasing IPH5201 and IPH5301 will be presented at #ESMOio22. Learn more: https://t.co/VyOro6IDWI @myESMO

0

19

7

0

Bertrand Delsuc @BertrandBio

almost 4 years ago

IPH5201 (anti-CD39) data in mono & combo with durva $IPH $IPHA $AZN #ESMOIO22 ORR 0% / 39% SD, mPFS 1.4mo, RP2D determined based on tgt saturation on immune cells

BertrandBio's tweet photo. IPH5201 (anti-CD39) data in mono & combo with durva $IPH $IPHA $AZN #ESMOIO22

ORR 0% / 39% SD, mPFS 1.4mo, RP2D determined based on tgt saturation on immune cells https://t.co/muImCMzVid

1

3

0

1

0

Bertrand Delsuc @BertrandBio

almost 4 years ago

The #ESMOIO22 non-LBA abstracts are released: https://t.co/1TD0cHfiHV

1

3

0

Bertrand Delsuc @BertrandBio

almost 4 years ago

$GMAB CEO talking high of GEN1042 CD40xPD-L1 notably in PDAC (combo with pembro & pembro-chemo), abstract out at #ESMOIO22 on Dec 1st, prez on Dec 8th

2

10

2

1

0

Bertrand Delsuc @BertrandBio

almost 4 years ago

$IPH $IPHA says anti-CD39 ( $AZN IPH5201) data in a poster at #ESMOIO22 (monotherapy & combo with durva) - cc @JacobPlieth

0

3

1

0

Top Tweets for #ESMOIO22

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users